FDA issued a third CRL for reproxalap, again concluding the NDA lacks substantial evidence of efficacy for dry eye signs and symptoms despite no safety/manufacturing deficiencies. Regulators ...

FDA rejection was attributed to a lack of substantial evidence of efficacy, including inconsistencies that undermined confidence in reproducibility across investigations. Reproxalap targets reactive ...

Watch the incredible moment of a complete ball python hatch. Former MPP's Freedom Convoy-related case back on after stay of charges overturned Eddie Vedder's 15-year fight for EB cure may be on the ...

Add Yahoo as a preferred source to see more of our stories on Google. Providence Mayor Brett Smiley, left, and Providence Police Chief Oscar Perez field reporters' questions during a City Hall ...

Regulatory emphasis shifts from ORR and response duration to MRD negativity and CR as surrogate endpoints intended to shorten development timelines by capturing deeper molecular responses. MRD ...

Microsoft has warned that information-stealing attacks are "rapidly expanding" beyond Windows to target Apple macOS environments by leveraging cross-platform languages like Python and abusing trusted ...

The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC) ...

Triple-negative breast cancer (TNBC) is a highly aggressive malignancy with limited therapeutic options and elevated mortality rates. Chemo-immunotherapy according to the KEYNOTE-522 has established a ...

Scores of employees are often hesitant to withdraw PF from their EPFO accounts due to a process which many find to be quite complex and time consuming. However, the central government is preparing to ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

The MarketWatch News Department was not involved in the creation of this content. interim, subject to change, and based on data available as of a specified data cutoff date. No conclusions regarding ...